The level of myeloid derived-suppressor cells in peripheral blood of patients with prostate cancerafter various types of therapy

Izabela Siemińska; Edyta Rychlicka-Buniowska; Janusz Jaszczyński; Mikołaj Palaczyński; Karolina Bukowska-Strakova; Janusz Ryś; Jan Dumański; Maciej Siedlar; Jarosław Baran

doi:10.5114/pjp.2020.95415

eISSN: 2084-9869
ISSN: 1233-9687

Polish Journal of Pathology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2020
vol. 71

Send email

Copy url:

abstract:

The level of myeloid derived-suppressor cells in peripheral blood of patients with prostate cancerafter various types of therapy

Izabela Siemińska

¹

,

Edyta Rychlicka-Buniowska

²

,

Janusz Jaszczyński

³

,

Mikołaj Palaczyński

³

,

Karolina Bukowska-Strakova

¹

,

Janusz Ryś

⁴

,

Jan Dumański

²

,

Maciej Siedlar

¹

,

Jarosław Baran

¹

Department of Clinical Immunology, Institute of Pediatrics, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
Department of Immunology, Genetics and Pathology, Medical Genetics and Genomics, Uppsala Universitet, Uppsala, Sweden
Department of Surgery, National Research Institute of Oncology, Krakow Branch, Krakow, Poland
Department of Pathology, National Research Institute of Oncology, Krakow Branch, Krakow, Poland

Pol J Pathol 2020; 71 (1): 46-54

DOI: https://doi.org/10.5114/pjp.2020.95415

Online publish date: 2020/05/20

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Siemińska I, Rychlicka-Buniowska E, Jaszczyński J, et al. The level of myeloid derived-suppressor cells in peripheral blood of patients with prostate cancerafter various types of therapy. Polish Journal of Pathology. 2020;71(1):46-54. doi:10.5114/pjp.2020.95415.

APA

Siemińska, I., Rychlicka-Buniowska, E., Jaszczyński, J., Palaczyński, M., Bukowska-Strakova, K.,  & Ryś, J. et al. (2020). The level of myeloid derived-suppressor cells in peripheral blood of patients with prostate cancerafter various types of therapy. Polish Journal of Pathology, 71(1), 46-54. https://doi.org/10.5114/pjp.2020.95415

Chicago

Siemińska, Izabela, Edyta Rychlicka-Buniowska, Janusz Jaszczyński, Mikołaj Palaczyński, Karolina Bukowska-Strakova, Janusz Ryś,  and Jan Dumański et al. 2020. "The level of myeloid derived-suppressor cells in peripheral blood of patients with prostate cancerafter various types of therapy". Polish Journal of Pathology 71 (1): 46-54. doi:10.5114/pjp.2020.95415.

Harvard

Siemińska, I., Rychlicka-Buniowska, E., Jaszczyński, J., Palaczyński, M., Bukowska-Strakova, K., Ryś, J., Dumański, J., Siedlar, M.,  and Baran, J. (2020). The level of myeloid derived-suppressor cells in peripheral blood of patients with prostate cancerafter various types of therapy. Polish Journal of Pathology, 71(1), pp.46-54. https://doi.org/10.5114/pjp.2020.95415

MLA

Siemińska, Izabela et al. "The level of myeloid derived-suppressor cells in peripheral blood of patients with prostate cancerafter various types of therapy." Polish Journal of Pathology, vol. 71, no. 1, 2020, pp. 46-54. doi:10.5114/pjp.2020.95415.

Vancouver

Siemińska I, Rychlicka-Buniowska E, Jaszczyński J, Palaczyński M, Bukowska-Strakova K, Ryś J et al. The level of myeloid derived-suppressor cells in peripheral blood of patients with prostate cancerafter various types of therapy. Polish Journal of Pathology. 2020;71(1):46-54. doi:10.5114/pjp.2020.95415.

PlumX metrics:

Prostate cancer is one of the most frequent cancers in men. Although several treatment options exist, their clinical effectiveness is still not satisfactory. One the possible reason of such situation might be the presence of myeloid-derived suppressor cells (MDSC) and their pro-tumorigenic activity. MDSC possess immunosuppressive ability and in many studies were shown to support tumor development and progression. In this study we addressed the question whether commonly used therapies of prostate cancer affect the level of MDSC populations in the patients’ blood. We compared the level of granulocytic (Gr-MDSC), monocytic (Mo-MDSC) and early stage MDSC (eMDSC) in the blood of patients at different clinical stage and different tumor grading scores, who underwent either surgery or hormonal therapy alone or were given a combined treatment, including e.g. radiotherapy. The obtained results showed that the level of Gr-MDSC was significantly lower in all treated patients comparing to untreated group. On the other hand, surgery or hormonal therapy alone did not affect the level of Mo-MDSC. These results were independent of the PSA level, the tumor grading and clinical stage of the patients. In conclusion, we suggest that Mo-MDSC should be considered as a potential therapy target in the course of prostate cancer treatment to enhance its anti-tumor effectiveness.

keywords:

The level of myeloid derived-suppressor cells in peripheral blood of patients with prostate cancerafter various types of therapy

Izabela Siemińska 1 , Edyta Rychlicka-Buniowska 2 , Janusz Jaszczyński 3 , Mikołaj Palaczyński 3 , Karolina Bukowska-Strakova 1 , Janusz Ryś 4 , Jan Dumański 2 , Maciej Siedlar 1 , Jarosław Baran 1

prostate cancer (PC), myeloid-derived suppressor cells (MDSC), flow cytometry, prostate specific antigen (PSA)

Izabela Siemińska

¹

,

Edyta Rychlicka-Buniowska

²

,

Janusz Jaszczyński

³

,

Mikołaj Palaczyński

³

,

Karolina Bukowska-Strakova

¹

,

Janusz Ryś

⁴

,

Jan Dumański

²

,

Maciej Siedlar

¹

,

Jarosław Baran

¹